Welcome to our dedicated page for Dermata Therapeutics news (Ticker: DRMA), a resource for investors and traders seeking the latest updates and insights on Dermata Therapeutics stock.
Dermata Therapeutics, Inc. develops dermatologic solutions and is repositioning its business around direct-to-consumer skincare under the Tome brand. Company updates center on OTC skincare concepts, including once-weekly acne and skin renewal products that use the company's Bioneedle and Spongilla technologies, as well as intellectual-property developments for Bioneedle Delivery System applications involving dermal fillers, botulinum toxin and hyperhidrosis.
Recurring Dermata news also includes financial results, private placements and at-the-market equity activity, along with management, marketing and board developments tied to its shift from pharmaceutical development toward consumer skincare products.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.